APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO	SERIAL NO.
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		HLZ-001US	10/019067
		APPLICANT: Mats Paulss n *et al.*	
		FILING DATE: June 28, 2002	GROUP: Not Yet Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
GC	A1	5,726,051	03/98	Fraij et al.	435	193	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
GC	A2	DE 19630557 A1	01/98	Germany			Abstr.	

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

GC	A3		Dietrich, W. *et al.* Identification of tissue transglutaminase as the autoantigen of celiac disease. *Nature Med.* 1997;3(7):797-801
GC	A4		Seissler, J. *et al.* Antibodies to human recombinant tissue transglutaminase measured by radioligand assay: evidence for high diagnostic sensitivity for celiac disease. *Horm. Metab. Res.* 1999 Jun;31(6):375-9
GC	A5		Sardy, M. *et al.* Recombinant human tissue transglutaminase ELISA for the diagnosis of gluten-sensitive enteropathy. *Clin. Chem.* 1999 Dec;45(12):2142-9

Examiner	/Gary Counts/	Date Considered	10/24/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	1

Complete if Known	
Application Number	10/019067-Conf. #7795
Filing Date	June 28, 2002
First Named Inventor	Mats PAULSSON
Art Unit	1641
Examiner Name	G. W. Counts
Attorney Docket Number	HLZ-001US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
GC	C1	International Search Report to PCT/EP00/06025 (June 28, 2000), 4 pages	
GC	C2	International Preliminary Examination Report for PCT/EP00/06025 (June 28, 2000), 7 pages	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Gary Counts/	Date Considered	10/24/2006

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-60	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO	SERIAL NO.
		HLZ-001US	10/019067
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT: Sardy, Miklos et al.	
		FILING DATE: December 21, 2001	GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

GC	A1		Andberg, M. et al. "Mutation of tyrosine 383 in leukotriene A_4 hydrolase allows conversion of leukotriene A_4 into 5S,6S-dihydroxy-7,9-trans-11,14-cis-eicosatetraenoic acid. Implications for the epoxide hydrolase mechanism," *J. Biol. Chem.* 1997 Sep 12;272(37):23057-63
GC	A2		Barrett, A.J. et al. Eds. "336. Introduction: family M1 of membrane alanyl aminopeptidase," in Handbook of proteolytic enzymes 1998 Oct; pp. 994-996
GC	A3		Blomster, M. et al. "Evidence for a catalytic role of tyrosine 383 in the peptidase reaction of leukotriene A_4 hydrolase," *Eur. J. Biochem.* 1995 Aug 1;231(3):528-34
GC	A4		Byrum, R.S. et al. "Determination of the contribution of cysteinyl leukotrienes and leukotriene B_4 in acute inflammatory responses using 5-lipoxygenase- and leukotriene A_4 hydrolase-deficient mice," *J. Immunol.* 1999 Dec 15;163(12):6810-9
GC	A5		Chen, X.-S. et al. "Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene," *Nature* 1994 Nov;372:179-182
GC	A6		Crameri, A. et al. "DNA shuffling of a family of genes from diverse species accelerates directed evolution," *Nature* 1998 Jan 15;391(6664):288-91
GC	A7		Devchand, P.R. et al. "The PPARalpha-leukotriene B_4 pathway to inflammation control," *Nature* 1996 Nov 7;384(6604):39-43
GC	A8		Dittmann, K.H. et al. "MK-886, a leukotriene biosynthesis inhibitor, induces antiproliferative effects and apoptosis in HL-60 cells," *Leuk. Res.* 1998 Jan;22(1):49-53
GC	A9		Drazen, J.M. et al. "Treatment of asthma with drugs modifying the leukotriene pathway," *N. Engl. J. Med.* 1999 Jan 21;340(3):197-206
GC	A10		Evans, J.F. "Leukotriene A_3. A poor substrate but a potent inhibitor of rat and human neutrophil leukotriene A_4 hydrolase," *J. Biol. Chem.* 1985 Sep 15;260(20):10966-70
GC	A11		Ford-Hutchinson, A.W. et al. "Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes," *Nature* 1980 July 17;286:264-65
GC	A12		Funk, C.D. et al. "Molecular cloning and amino acid sequence of leukotriene A_4 hydrolase," *Proc. Natl. Acad. Sci. USA* 1987 Oct;84(19):6677-81
GC	A13		Griffiths, R.J. et al. "Leukotriene B_4 plays a critical role in the progression of collagen-induced arthritis," *Proc. Natl. Acad. Sci. USA* 1995 Jan 17;92(2):517-21
GC	A14		Griffiths, R.J. et al. "Collagen-induced arthritis is reduced in 5-lipoxygenase-activating protein-deficient mice," *J. Exp. Med.* 1997 Mar 17;185(6):1123-9

Examiner	/Gary Counts/	Date Considered	10/24/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO	SERIAL NO.
		HLZ-001US	10/019067
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT: Sardy, Miklos et al.	
		FILING DATE: December 21, 2001	GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

GC	B1		Haeggström, J.Z. et al. "Leukotriene A_4 hydrolase: structural and functional properties of the active center," *J. Lipid Mediat.* 1993 Mar-Apr;6(1-3):1-13
GC	B2		Hogg, J.H. et al. "Probing the activities and mechanisms of leukotriene A_4 hydrolase with synthetic inhibitors," *Chem. Eur. J.* 1998;4(9):1698-1713
GC	B3		Kuchner, O. et al. "Directed evolution of enzyme catalysts," *Trends Biotechnol.* 1997 Dec;15(12):523-30
GC	B4		Labaudinière, R. et al. "ω -[(ω-Arylalkyl)thienyl]alkanoic acids: from specific LTA_4 hydrolase inhibitors to LTB_4 receptor antagonists," *J. Med. Chem.* 1992 Aug 21;35(17):3170-9
GC	B5		Lewis, R.A. et al. "Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases," *N. Engl. J. Med.* 1990 Sep 6;323(10):645-55
GC	B6		Lorsch, J.R. et al. "In vitro evolution of new ribozymes with polynucleotide kinase activity," *Nature* 1994 Sep 1;371(6492):31-6
GC	B7		Medina, J.F. et al. "Leukotriene A_4 hydrolase: determination of the three zinc-binding ligands by site-directed mutagenesis and zinc analysis," *Proc. Natl. Acad. Sci. USA* 1991 Sep 1;88(17):7620-4
GC	B8		Ménard, A. et al. "The cytotoxic activity of Bacillus anthracis lethal factor is inhibited by leukotriene A_4 hydrolase and metallopeptidase inhibitors," *Biochem. J.* 1996 Dec 1;320 (Pt 2):687-91
GC	B9		Mueller, M.J. et al. "Leukotriene A_4 hydrolase: mapping of a henicosapeptide involved in mechanism-based inactivation," *Proc. Natl. Acad. Sci. USA* 1995 Aug 29;92(18):8383-7
GC	B10		Mueller, M.J. et al. "Leukotriene A_4 hydrolase: protection from mechanism-based inactivation by mutation of tyrosine-378," *Proc. Natl. Acad. Sci. USA* 1996 Jun 11;93(12):5931-5
GC	B11		Mueller, M.J. et al. "Leukotriene A_4 hydrolase, mutation of tyrosine 378 allows conversion of leukotriene A_4 into an isomer of leukotriene B_4," *J. Biol. Chem.* 1996 Oct 4;271(40):24345-8
GC	B12		Nord, K. et al. "Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain," *Nat. Biotechnol.* 1997 Aug;15(8):772-7
GC	B13		Orning, L. et al. "Inhibition of leukotriene A_4 hydrolase/aminopeptidase by captopril," *J. Biol. Chem.* 1991 Sep 5;266(25):16507-11
GC	B14		Orning, L. et al. "The bifunctional enzyme leukotriene- A_4 hydrolase is an arginine aminopeptidase of high efficiency and specificity," *J. Biol. Chem.* 1994 Apr 15;269(15):11269-73

Examiner	/Gary Counts/	Date Considered	10/24/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO	SERIAL NO.
		HLZ-001US	10/019067
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT: Sardy, Miklos et al.	
		FILING DATE: December 21, 2001	GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

GC	C1		Owman, C. et al. "The leukotriene B_4 receptor functions as a novel type of coreceptor mediating entry of primary HIV-1 isolates into CD4-positive cells," *PNAS. USA* 1998 Aug 4;95(16):9530-4
GC	C2		Rola-Pleszczynski, M. et al. "Leukotrienes augment interleukin 1 production by human monocytes," *J. Immunol.* 1985 Dec;135(6):3958-61
GC	C3		Samuelsson, B. "Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation," *Science* 1983 May 6;220(4597):568-75
GC	C4		Samuelsson, B. et al. "Leukotrienes and lipoxins: structures, biosynthesis, and biological effects," *Science* 1987 Sep 4;237(4819):1171-6
GC	C5		Serhan, C.H. et al. "Lipid mediator networks in cell signaling: update and impact of cytokines," *FASEB J.* 1996 Aug;10:1-12
GC	C6		Tsuge, H. et al. "Crystallization and preliminary X-ray crystallographic studies of recombinant human leukotriene A_4 hydrolase complexed with bestatin," *J. Mol. Biol.* 1994 May 20;238(5):854-6
GC	C7		Vallee, B.L. et al. "Active-site zinc ligands and activated H_2O of zinc enzymes," *Proc. Natl. Acad. Sci. USA* 1990 Jan;87(1):220-4
GC	C8		Wetterholm, A. et al. "Recombinant mouse leukotriene A_4 hydrolase: a zinc metalloenzyme with dual enzymatic activities," *Biochim. Biophys. Acta* 1991 Oct 25;1080(2):96-102
GC	C9		Wetterholm, A. et al. "Leukotriene A_4 hydrolase: abrogation of the peptidase activity by mutation of glutamic acid-296," *Proc. Natl. Acad. Sci. USA* 1992 Oct 1;89(19):9141-5
GC	C10		Wetterholm, A. et al. "Potent and selective inhibitors of leukotriene A_4 hydrolase: effects on purified enzyme and human polymorphonuclear leukocytes," *J. Pharmacol. Exp. Ther.* 1995 Oct;275(1):31-7
GC	C11		Yamaoka, K.A. et al. "Leukotriene B_4 enhances activation, proliferation, and differentiation of human B lymphocytes," *J. Immunol.* 1989 Sep 15;143(6):1996-2000
GC	C12		Yokomizo, T. et al. "A G-protein-coupled receptor for leukotriene B_4 that mediates chemotaxis," *Nature* 1997 Jun 5;387(6633):620-4
GC	C13		Yokomizo, T. et al. "A second leukotriene B_4 receptor, BLT2. A new therapeutic target in inflammation and immunological disorders," *J. Exp. Med.* 2000 Aug 7;192(3):421-32
GC	C14		Yuan, W. et al. "Novel tight-binding inhibitors of leukotriene A_4 hydrolase," *J. Am. Chem. Soc.* 1992 April;114:6552-53
GC	C15		GenPept Acc. No. S65947; leukotriene-A4 hydrolase (EC 3.3.2.6) long isoform - human

Examiner	/Gary Counts/	Date Considered	10/24/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.